PPARA and hepatocellular carcinoma: In humans, chronic treatment with PPARα agonists, such as gemfibrozil and fenofibrate, does not induce peroxisome proliferation or HCC and instead provides lipid-lowering benefits with a favorable safety profile in hyperlipidemic patients [89,90,91].